Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPriority Health Medicare MPSERS Formulary Coverage…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Currentpriority healthPolicy N/A

    Priority Health Medicare MPSERS Formulary (Drug List) - Coverage Criteria

    Customize your policy alerts

    Sign up for all priority health policy alerts

    Know when priority health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Describes the prescription drugs covered by the Priority Health Medicare MPSERS plan, applicable rules (prior authorization, quantity limits, step therapy), and how members and prescribers can request exceptions or transition supplies.

    Policy Summary
    Payerpriority health
    PolicyPriority Health Medicare MPSERS Formulary (Drug List) - Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Last ReviewMay 21, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when 'PA' is listed for a drug before dispensing to avoid denial of coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    05/21/2026formulary last updated
    30-daytransition supply
    PA commonPA present
    QL presentQuantity limits
    T1-T6tiers used

    Coverage and Formulary Rules

    General coverage conditions

    Covered when ALL of the following are met

    Basic coverage conditions: Drug is listed on the Priority Health Medicare formulary; drug is medically necessary; prescription is filled at a Priority Health Medicare network pharmacy; other plan rules (e.g., PA, QL, ST) are followed.

    From formulary overview

    Formulary drug-level coverage rules

    Coverage and management rules are applied per drug as listed; common rules include prior authorization (PA), quantity limits (QL), step therapy (ST), No Express Scripts (NE), Home Infusion (HI), and Part B vs Part D (B/D).

    Per-drug management: Each drug entry includes a tier and may include one or more management requirements (PA, QL, ST, NE, HI, LA, B/D). Coverage of a drug is governed by the listed tier and any listed requirements.

    Providers must follow the specific requirement(s) shown next to each drug when prescribing or dispensing.

    Policy Summary
    Payerpriority health
    PolicyPriority Health Medicare MPSERS Formulary (Drug List) - Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Last ReviewMay 21, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when 'PA' is listed for a drug before dispensing to avoid denial of coverage.
    SourceLink
    On This Page
    Coverage and Formulary RulesAbbreviations, Tiers, and Quantity ExamplesPrior Authorization, Step Therapy, and DocumentationPer-Product Quantity Limit DetailsHome Infusion and Benefit DeterminationsTerminology and Abbreviation KeyStep Therapy Rules and Affected AgentsBiosimilar Substitution and TieringPolicy Background and Scope

    Formulary coverage with utilization management

    Coverage and utilization management as listed on the formulary for each drug

    Formulary coverage logic: Drug coverage depends on formulary tier and listed Requirements/Limits (e.g., PA, QL, LA). Many specialty oral oncology drugs are Tier 5 and require prior authorization and have quantity limits.

    Per-drug requirements are listed alongside each product in the document.

    Coverage by tier with PA/QL annotations

    Formulary coverage is indicated by drug tier and may include PA or QL conditions as listed per product and strength.

    Formulary listing rule: A drug is placed on a formulary tier (T1-T6) and may have an associated requirement: prior authorization (PA), quantity limits (QL), home infusion (HI), or Part B vs Part D designation (B/D).

    Specific clinical criteria for PA are not provided in this segment; only the presence of PA/QL is shown.

    Coverage conditions (partial)

    Coverage and access depend on drug-specific rules below (as listed):

    Prior Authorization required: Drugs explicitly labeled with 'PA' require prior authorization before coverage (examples in these chunks include OTEZLA 30 mg, PANRETIN, carglumic acid, tolvaptan, RELISTOR, AMVUTTRA, ENDARI, PROLASTIN-C and others).

    Providers must obtain PA where indicated.

    Quantity Limits: Drugs labeled with 'QL' have explicit maximum quantities per time period (examples: 120 GM per 30 days; 60 EA per 30 days; 90 EA per 30 days).see specific product entries

    Prescriptions exceeding QL may be denied or require PA.

    Excluded Drugs: Drugs labeled 'ED' are excluded from coverage (examples: RENOVA, RENOVA PUMP, urea products, certain vitamin preparations).

    Requests for ED products are not covered unless an exception is granted.

    Home Infusion / Limited Availability: Some parenteral or infusion products are marked 'HI' (Home Infusion) or 'LA' (Limited Availability) which affects site-of-care coverage and procurement (examples: magnesium sulfate injection, PROLASTIN-C noted LA).

    Site-of-care or supplier requirements may apply.

    Step Therapy: Some products indicate 'ST' (step therapy), meaning preferred alternatives may be required first (e.g., clotrimazole-betamethasone cream shows ST).

    Step therapy requirements must be met for coverage.

    Coverage determination logic

    Formulary coverage and administrative controls apply as listed below for each agent.

    Formulary tier and requirement logic: Coverage status determined by assigned tier (T1–T6) and any listed Requirements/Limits (PA, QL, B/D, LA). For Tier 5 specialty drugs many entries require PA and have QL; Part B vs Part D (B/D) applies for some agents.

    Operational: submit PA when indicated and observe QL limits.

    Prior authorization required group

    Coverage actions in these chunks (applies to listed specialty/high-cost agents):

    Specialty/pulmonary agents requiring PA: Drugs such as CAYSTON, KALYDECO, ORKAMBI, TRIKAFTA, ADEMPAS, ambrisentan, bosentan, OPSUMIT, ORENITRAM, nintedanib, OFEV, pirfenidone, and other specialty pulmonary or cystic fibrosis agents are listed with 'PA' indicating prior authorization is required; many also have QL and/or LA.

    Coverage requires prior authorization where PA is noted

    Quantity limits

    Drugs covered with quantity limits:

    Quantity-limited drugs: Multiple inhalers, nebulizers, dermatologic and specialty products include specified QLs (examples: epinephrine auto-injector 4 EA per 30 days; QVAR REDIHALER 21.2 GM per 30 days; BREYNA 10.3 GM per 30 days; INCRUSE/ANORO/TRELEGY/WIXELA QL 30-60 EA per 30 days; KALYDECO/ORKAMBI/TRIKAFTA with specified EA per 28/30 days).See individual drug QLs in list

    Claims exceeding QL may be limited or require justification.

    Drugs marked ED (Excluded Drug) on the formulary are not normally covered under a Medicare Prescription Drug Plan. Amounts paid by the member for ED drugs do not count toward total drug costs

    The formulary defines ED in the abbreviations list as Excluded Drug: a prescription drug that is not normally covered in a Medicare Prescription Drug Plan. The document notes ED in the legend along with tier definitions and requirement codes used across the drug list.

    Within this segment of the document there are no explicit standalone exclusion statements beyond the legend definition; excluded products would be identified on the line items with the ED flag when present.

    Examples of items marked ED in the formulary include topical and supplement products such as RENOVA / RENOVA PUMP, various vitamin preparations and folate formulations, and certain urea external preparations (e.g., urea nail gel). These ED-marked items are shown in the drug listings as excluded from coverage.

    Multiple individual products are flagged ED across the list — examples shown include many vitamin/mineral combinations (e.g., folplex, folbee formulations) and other branded items where the Requirements/Limits column indicates ED instead of coverage controls.

    Several infertility-related products are specifically listed as ED, for example intramuscular chorionic gonadotropin and certain hCG injection preparations; these items are placed on Tier 6 (infertility) and marked excluded in the Requirements/Limits field.

    The abbreviations/key at the front of the formulary explicitly defines plan codes including ED = Excluded Drug, alongside other requirement codes (PA, QL, ST, HI, LA, B/D) and tier definitions (T1–T6).

    Specific examples of excluded drugs elsewhere in the formulary include respiratory items such as certain sodium chloride inhalation nebulization solutions and benzonatate, each shown with ED in the Requirements/Limits column and therefore not covered.

    The document does not use the phrase 'not medically necessary' in these chunks; instead it uses the ED designation to indicate products that are excluded from formulary coverage.

    Abbreviations, Tiers, and Quantity Examples

    Abbreviations related to coveragemixed
    B/DPart B vs Part D; may require prior authorization and documentation to determine coverage setting
    Quantity Limit examplesmixed
    QL (example)Quantity limits listed per drug, e.g., QL (750 ML per 30 days), QL (60 EA per 30 days)
    Formulary tiersmixed
    T1-T6Formulary tier indicators (T1 Preferred generic to T6 Infertility)
    Formulary listings (no billing codes present)mixed
    No codes listed
    Drug list (no CPT/ICD codes in this segment)mixed
    No codes listed
    Formulary requirement codes and abbreviationsmixed
    QL (e.g., 60 EA per 30 days)Quantity Limit examples shown for many products (exact values vary by product and strength)
    PAPrior Authorization required (as noted for certain products)
    HIHome Infusion designation (e.g., heparin sodium listed as HI)
    B/DPart B vs Part D billing designation (used for certain injectables/biologics)
    Formulary drug entries (partial list)mixed
    OTEZLA ORAL TABLET 30 MGDrug entry shown with Tier 5; Requirements: PA; QL (60 EA per 30 days)
    PANRETINTier 5; Requirements: PA; QL (60 GM per 30 days)
    clotrimazole-betamethasone external creamTier 2; Requirements: ST; QL (120 GM per 30 days)
    fluorouracil external cream 5%Tier 2; Requirements: QL (40 GM per 30 days)
    imiquimod external cream 5%Tier 4; Requirements: none listed in these chunks
    methoxsalen rapidTier 5; Requirements: none listed in these chunks
    nystatin-triamcinoloneTier 2; Requirements: none listed in these chunks
    SANTYLTier 4; Requirements: QL (60 GM per 30 days)
    silver sulfadiazine (ssd)Tier 2; Requirements: none listed
    tretinoin (emollient)Tier 3; Requirements: ED
    1–10 of 20
    1/2
    Hormonal/Thyroid agentsmixed
    ARMOUR THYROIDARMOUR THYROID (listed drug)
    levothyroxine sodium oral tabletlevothyroxine sodium oral tablet
    levoxyllevoxyl
    liothyronine sodium oralliothyronine sodium oral
    NP THYROIDNP THYROID
    SYNTHROIDSYNTHROID
    unithroidunithroid
    Hormonal agents (pituitary / GnRH modulators)mixed
    FIRMAGON 240 MGFIRMAGON (240 MG DOSE)
    FIRMAGON 80 MGFIRMAGON SUBCUTANEOUS SOLUTION RECONSTITUTED 80 MG
    lanreotide acetatelanreotide acetate
    Somatostatin analogs and depot formulationsmixed
    LUPRON DEPOT 1-MONTH 3.75 MGLUPRON DEPOT (1-MONTH) INTRAMUSCULAR KIT 3.75 MG
    LUPRON DEPOT 3-MONTH 11.25 MGLUPRON DEPOT (3-MONTH) INTRAMUSCULAR KIT 11.25 MG
    octreotide acetate injection solutionoctreotide acetate injection solution (multiple concentrations)
    SOMATULINE DEPOT 60/90 MGSOMATULINE DEPOT SUBCUTANEOUS SOLUTION 60 MG/0.2ML, 90 MG/0.3ML
    Antithyroid agentsmixed
    methimazole oralmethimazole oral
    propylthiouracil oralpropylthiouracil oral
    Biologics with PA and QLmixed
    COSENTYX (300 MG DOSE)COSENTYX (300 MG DOSE) — PA; QL (8 ML per 28 days)
    DUPIXENT various strengthsDUPIXENT (multiple presentations) — PA; QL (various per 30 days)
    SKYRIZI productsSKYRIZI (multiple presentations) — PA; QL (1 ML per 28 days or as listed)
    ustekinumab-aeknustekinumab-aekn (45 mg/0.5ml and 90 mg/ml) — PA; QL
    Other specialty agentsmixed
    XELJANZ (various)XELJANZ oral solution/tablet/XR — PA; QL examples provided
    XOLAIR (various)XOLAIR subcutaneous (auto-injector, prefilled syringe, reconstituted) — PA; some LA
    Chemotherapies/immunomodulators and vaccinesmixed
    methotrexate sodium injection/ oralmethotrexate sodium (injection and oral) — tiers listed
    vaccines (abrysvo, ACTHIB, ADACEL, BEXSERO, BOOSTRIX, etc.)Vaccine listings with tiers and occasional QL or B/D
    Formulary codes and limitsmixed
    QL (30.5 GM per 30 days)Quantity limit for olopatadine hcl nasal
    QL (30 EA per 30 days)Quantity limit for ARNUITY ELLIPTA
    B/DPart B vs Part D designation (applies to listed formulations such as budesonide inhalation suspensions)
    QL (21.2 GM per 30 days)Quantity limit for QVAR REDIHALER
    QL (30 EA per 30 days)Quantity limit for INCRUSE ELLIPTA
    QL (4 GM per 30 days)Quantity limit for SPIRIVA RESPIMAT
    QL (17 GM per 30 days)Quantity limit for certain albuterol HFA formulation
    QL (13.4 GM per 30 days)Quantity limit for a specific albuterol HFA NDA
    QL (36 GM per 30 days)Quantity limit for another albuterol HFA NDA
    QL (60 EA per 30 days)Quantity limit for multiple ellipta/inhaler combination products (e.g., BREO, ANORO, WIXELA, TRELEGY, etc.)
    1–10 of 15
    1/2
    Transition / Temporary Supply
    Transition/temporary supply30-day temporary supply for non-formulary or restricted drugs; 31-day emergency supply for long-term care residents under certain circumstances
    Supply during membership transitionMembers may receive a transition supply of at least 30 days when starting the plan (or up to the written days if less), to allow time for exception requests
    Exception processMembers/prescribers may request a formulary exception; prescriber must provide supporting medical statement; decision timelines: standard 72 hours, expedited 24 hours
    Example quantity limits (QL examples)
    Example QL — topical dermatologics (GM)fluorouracil external cream 5% QL 40 GM per 30 days; clotrimazole-betamethasone external cream QL 120 GM per 30 days
    Example QL — external/topical (varied GM/ML)imiquimod external cream 5% (listed), SANTYL QL 60 GM per 30 days, silver sulfadiazine (ssd) listed
    Example QL — antimicrobials and topical antibioticsmupirocin external QL 44 GM per 30 days; mupirocin calcium QL 60 GM per 30 days; acyclovir external ointment QL 30 GM per 30 days; ciclopirox formulations with QLs (100 GM, 120 ML, 6.6 ML)
    Example QL — pediculicides/scabicides and scabiespermethrin external cream QL 120 GM per 30 days; ivermectin external cream QL 45 GM per 30 days
    Example QL — topical clindamycin formulationsclindamycin phosphate external gel/lotion/solution QL 60 GM/ML per 30 days depending on formulation
    Example QL — common topical QLs (GM examples)QL examples shown across formulary: 120 GM/30 days; 60 GM/30 days; 45 GM/30 days; 40 GM/30 days
    Quantity Limits examples (antimicrobials and others)
    Antimicrobials — oral/IV/other QLslinezolid oral tablet QL 56 EA per 28 days; vancomycin oral capsule 125 mg QL 80 EA per 30 days; vancomycin 250 mg QL 160 EA per 30 days; DIFICID oral suspension QL 136 ML per 10 days; DIFICID tablets QL 20 EA per 10 days
    Anticonvulsants/neurology examplesbrivaracetam oral solution QL 600 ML per 30 days; eslicarbazepine acetate 200/400 mg QL 30 EA per 30 days and 600/800 mg QL 60 EA per 30 days; lacosamide oral solution QL 1200 ML per 30 days
    Dermatology/topicals examplesciclopirox external gel QL 100 GM per 30 days; ciclopirox shampoo QL 120 ML per 30 days; clindamycin phosphate topical forms QL 60 GM/ML per 30 days
    Inhaled/respiratory & inhaler QLsfluticasone-salmeterol inhaler QL 1 EA per 30 days (or 60 EA per 30 days depending on product); QVAR REDIHALER QL 21.2 GM per 30 days; epinephrine auto-injector QL 4 EA per 30 days
    Biologic/SC injection QLsCOSENTYX 300 mg QL 8 ML per 28 days; DUPIXENT QL 3.42 ML (200 mg) up to 8 ML (300 mg) per 30 days; SKYRIZI QLs vary by presentation (1 ML per 28 days; 1.2 ML or 2.4 ML per 56 days)
    Vaccine/long-interval QLs
    Quantity limits examples (neurology/antiseizure examples)
    Oral anticancer/oncology QLs (EA per period)Multiple oral oncology agents have product-specific QLs (examples: PIQRAY QL 56 EA per 28 days; KISQALI QL 49–91 EA per 28 days depending on dose; many agents require PA and QLs as listed)
    High-volume oral solution QLsVITRAKVI oral solution QL 300 ML per 30 days; brivaracetam oral solution QL 600 ML per 30 days; ISENTRESS solutions QL ranges 60–300 per 30 days
    Enoxaparin and parenteral ML QLsEnoxaparin prefilled syringes: 30 mg QL 18 ML/30 days; 40 mg QL 24 ML/30 days; 60 mg QL 36 ML/30 days
    REPATHA biologic QLsREPATHA QL 2 ML per 28 days; REPATHA PUSHTRONEX QL 3.5 ML per 30 days; REPATHA SURECLICK QL 2 ML per 28 days
    Neurology/stimulant solution QLmethylphenidate oral solution 10 mg/5 ml QL 1500 ML per 30 days; pregabalin capsule QL 90 EA per 30 days
    Quantity limits examples (common counts)
    Common EA counts — examplesXARELTO 10 mg QL 30 EA per prescription; morphine ER QL examples: 60 or 120 EA per 30 days depending on strength; many oral agents show EA-based QLs (e.g., 30, 56, 60, 90, 120 EA)
    Common ML volumes — examplesSodium channel agents group QL 1100 ML per 30 days; lacosamide solution QL 1200 ML per 30 days; IV/solution QLs for enoxaparin and other injectables provided in ML
    Common GM weights — examplesTopical/gm QLs include BREYNA 10.3 GM per 30 days; QVAR REDIHALER 21.2 GM per 30 days; clotrimazole-betamethasone cream 120 GM per 30 days
    Per-pack/long-interval countsVaccine and specialty products have long intervals (e.g., SHINGRIX 1 ML per 999 days; MRESVIA 0.5 ML per 720 days; PENBRAYA 2 EA per 720 days)
    Quantity limits examples (varied ranges)
    Per-drug exact QL examples (selection)XARELTO oral suspension QL 620 ML per 30 days; INVEGA HAFYERA QLs 3.5 ML–5 ML per 180 days depending on strength; enoxaparin QLs 18–36 ML per 30 days
    Respiratory/inhaler rangesFluticasone-salmeterol inhalers QL 1 EA per 30 days or 60 EA per 30 days depending on presentation; INCRUSE/ANORO/TRELEGY QLs 30–60 EA per 30 days
    Pulmonary and CF agent QLsKALYDECO QL 56 EA per 28 days; ORKAMBI QL 60 EA per 30 days; TRIKAFTA QLs vary as listed; CAYSTON listed PA and LA
    Long-interval biologic/osteoporosis QLsEVENITY QL 2.34 ML per 30 days; TERIPARATIDE QL 2.48 ML per 30 days; BILDYOS QL 1 ML per 180 days
    Quantity limits examples (TRIJARDY XR etc.)
    Selected ML examples for biologics/solutionsREPATHA 2 ML per 28 days; REPATHA PUSHTRONEX 3.5 ML per 30 days; COSENTYX 8 ML per 28 days; icatibant/SAJAZIR QL 18 ML per 30 days
    Selected EA examples for specialty packsPIQRAY QL 56 EA per 28 days; INVEGA TRINZA QLs per 90 days (e.g., 0.88 ML/90 days); OTEZLA QL 60 EA per 30 days (tablet)
    Selected GM examplesBREYNA QL 10.3 GM per 30 days; QVAR REDIHALER QL 21.2 GM per 30 days; olopatadine hcl nasal QL 30.5 GM per 30 days
    High-volume solution examplesmethylphenidate solution QL 1500 ML per 30 days; brivaracetam solution QL 600 ML per 30 days; VITRAKVI solution QL 300 ML per 30 days
    Quantity limits examples (biologic mL examples)
    Selected biologic mL examplesDUPIXENT 200 mg presentation QL 3.42 ML per 30 days; COSENTYX 300 mg QL 8 ML per 28 days; SKYRIZI QLs 1–2.4 ML per 28/56 days depending on presentation
    Selected inhaler/respiratory mL/EA examplesQVAR REDIHALER 21.2 GM per 30 days; fluticasone-salmeterol inhaler QL 1 EA per 30 days or 60 EA; epinephrine auto-injector QL 4 EA per 30 days
    Selected long-interval vaccine/therapy examplesMRESVIA QL 0.5 ML per 720 days; PENBRAYA QL 2 EA per 720 days; VIVOTIF QL 4 EA per 720 days; SHINGRIX 1 ML per 999 days (prefill)
    Selected quantity limits (long-interval vaccines/therapies)
    Selected long-interval vaccines/therapiesMRESVIA QL 0.5 ML per 720 days; PENBRAYA QL 2 EA per 720 days; VIVOTIF QL 4 EA per 720 days; SHINGRIX QL 1 ML per 999 days (prefill) or 2 EA per 999 days (reconstituted)
    Examples — infrequent dosing agentsBILDYOS QL 1 ML per 180 days; EVENITY QL 2.34 ML per 30 days; TERIPARATIDE QL 2.48 ML per 30 days; TYMLOS QL 1.56 ML per 30 days
    Vaccine pack examplesPENBRAYA and penmenvy QL 2 EA per 720 days; VIVOTIF QL 4 EA per 720 days
    Quantity limits examples (varied per-drug examples)
    Example QL — small mass/volume valuesBREYNA QL 10.3 GM per 30 days; olopatadine hcl nasal QL 30.5 GM per 30 days; QVAR REDIHALER QL 21.2 GM per 30 days
    Example QL — common EA per monthTypical EA QLs include 30 EA, 60 EA, 90 EA, 120 EA per 30 days for many oral products (values vary by product/strength)
    Example QL — specialized per-drug valuesXIFAXAN 200 mg QL 9 EA per 30 days; XIFAXAN 550 mg QL 60 EA per 30 days; DIFICID suspension QL 136 ML per 10 days

    Prior Authorization, Step Therapy, and Documentation

    Prior Authorization

    Prior authorization requirement

    Priority Health Medicare requires prior authorization (PA) for certain drugs; providers or prescribers must obtain PA approval from Priority Health Medicare before the prescription is filled or the plan may not cover the drug.

    • PA is required where 'PA' is shown in the Requirements/Limits column on the formulary.
    • Failure to obtain PA may result in noncoverage of the drug.
    Prior Authorization

    Prior Authorization Requirement

    Priority Health Medicare requires prior authorization (PA) for drugs annotated 'PA' in the formulary; prescribers must submit a PA request specifying the product, strength, and quantity before dispensing.

    • PA must be obtained prior to filling when the formulary entry shows 'PA'.
    • Tier 5 specialty drugs commonly require PA and are limited to a 30‑day supply.
    Prior Authorization

    PA required for select specialty and listed products

    Certain specialty and select products explicitly list 'PA' next to the drug (examples include XIFAXAN 200 mg/550 mg, DIFICID, many anticonvulsants); prescribers must obtain PA as indicated on each drug line.

    • XIFAXAN 200 mg — PA; QL (9 EA/30 days); XIFAXAN 550 mg — PA; QL (60 EA/30 days).
    • DIFICID oral suspension/tablet — ST; QL (136 mL/10 days or 20 EA/10 days).
    • Multiple anticonvulsants (e.g., brivaracetam) list PA and QL.
    Prior Authorization

    Prior authorization required for listed specialty and select agents

    Many specialty and select agents listed across the formulary require prior authorization (PA); providers must check each formulary entry and obtain PA for those products before coverage is approved.

    • Examples include eslicarbazepine acetate (PA; QL), rufinamide (PA), AUVELITY (PA; QL; NE).
    • Oncology and specialty oral agents frequently show PA in Requirements/Limits.
    Prior Authorization

    Prior Authorization Requirement for oncology oral agents

    Prior authorization is required for many oral oncology and molecular-targeted agents shown as Tier 5 with 'PA' in the Requirements/Limits column; obtain PA before prescribing these oral oncology drugs to avoid denial.

    • Examples: PIQRAY, QINLOCK, many molecular target inhibitors list PA and QL.
    • Tier 5 oral oncology drugs are commonly subject to PA and QL.
    Prior Authorization

    PA required for many specialty drugs

    Numerous specialty drugs throughout the formulary require prior authorization (PA); providers should review each drug entry for a PA flag and submit authorization requests accordingly.

    • Specialty oral oncology and other Tier 5 products routinely indicate PA in Requirements/Limits.
    • See the drug listing for product‑specific PA and QL values.
    Prior Authorization

    Prior authorization required (examples: VERSACLOZ, LIVTENCITY, PREVYMIS)

    Certain high-cost or specialty agents are explicitly listed with 'PA' (examples include VERSACLOZ, LIVTENCITY, PREVYMIS); providers must obtain PA for these products to secure coverage.

    • VERSACLOZ — PA; QL (540 mL per 30 days).
    • LIVTENCITY — PA; QL (336 EA per 28 days).
    • PREVYMIS (oral packet/tablet) — PA; QL (120 EA per 30 days).
    Prior Authorization

    Prior authorization required for listed items (examples)

    Several listed devices, injectables, and supply items require prior authorization (PA) per the formulary entries; obtain PA for those items listed with 'PA' to avoid claim denials.

    • Examples include TRULICITY auto‑injector (PA; QL 2 mL/28 days) and various pen needles/syringes listed with PA.
    • Some supplies and devices show PA in Requirements/Limits.
    Prior Authorization

    Prior authorization required for select drugs (NEXLETOL, REPATHA examples)

    Prior authorization is required for select cardiovascular/lipid agents and biologics shown with 'PA' (examples include NEXLETOL, NEXLIZET, REPATHA variants); submit PA requests per the formulary entry.

    • NEXLETOL/NEXLIZET — PA; QL (30 EA per 30 days).
    • REPATHA and REPATHA PUSHTRONEX — PA with specified QLs (2 mL per 28 days; 3.5 mL per 30 days).
    Prior Authorization

    Prior Authorization Required (general reminder to providers)

    This is a reminder that prior authorization (PA) is required where indicated on the formulary; providers must obtain PA before dispensing to ensure coverage.

    • Check the Requirements/Limits column on each drug line for 'PA'.
    • Failure to obtain PA may result in noncoverage.
    Prior Authorization

    Prior authorization required (examples across chunks)

    Multiple formulary examples across sections show PA flags; providers must submit prior authorization requests for those products (see product lines for exact PA/Q L annotations).

    • Sodium channel agents group — PA; QL examples shown.
    • Eslicarbazepine acetate and many anticonvulsants have PA noted.
    Prior Authorization

    Prior Authorization requirement for Tier 5 specialty and branded products

    Prior authorization is required for many Tier 5 specialty and branded products; providers must secure PA prior to dispensing these specialty medications to avoid coverage denial.

    • Cosentyx, Dupixent, Skyrizi and other biologics show PA with QL.
    • Tier 5 specialty products are frequently PA‑controlled and limited to 30‑day supplies.
    Prior Authorization

    PA required for select specialty agents

    PA is required for a broad set of specialty agents identified in the formulary; providers must request PA for those agents flagged with 'PA' to obtain plan coverage.

    • Examples include BILPREVDA, EVENITY, TERIPARATIDE, TYMLOS — shown with PA and/or QL.
    • Specialty/high‑cost agents listed with PA will not be covered without authorization.
    Prior Authorization

    Prior authorization required for specified specialty agents

    Selected pulmonary, cystic fibrosis, pulmonary hypertension and pulmonary fibrosis agents are listed with 'PA' — providers must obtain prior authorization for these specified specialty agents before coverage.

    • CAYSTON, KALYDECO, ORKAMBI, TRIKAFTA — PA; many with QL and some with LA.
    • Pulmonary antihypertensives (ADEMPAS, ambrisentan, bosentan, etc.) list PA; QL values provided.
    Step Therapy

    Step therapy requirement (overview)

    Step therapy (ST) may require that the member try specified lower‑step drugs before an alternative will be covered; providers must follow ST requirements where indicated on the formulary.

    • ST is shown in the formulary abbreviations and applies when 'ST' is listed next to a drug.
    • Providers should document prior agent failure or intolerance when requesting exceptions.
    Step Therapy

    Step Therapy (general requirement)

    Some drugs are subject to step therapy (ST); members must try specified first‑line drugs before alternatives are covered and providers should submit documentation showing prior trials.

    • ST is used where indicated in the Requirements/Limits column (e.g., FETZIMA lists ST).
    • If step requirements are not met, coverage may be denied.
    Step Therapy

    Step therapy for DIFICID

    DIFICID (fidaxomicin) oral suspension and tablets are listed with Step Therapy (ST) and quantity limits; providers must follow the ST requirement and request PA if required.

    • DIFICID oral suspension — ST; QL 136 mL per 10 days.
    • DIFICID oral tablet — ST; QL 20 EA per 10 days.
    Step Therapy

    Step therapy applies where indicated (examples)

    Step therapy applies to specific agents where 'ST' is indicated (examples include FETZIMA, TRINTELLIX, eletriptan); providers must ensure required prior therapy has been tried or submit an exception.

    • FETZIMA — ST; QL 30 EA per 30 days.
    • Eletriptan — ST; QL (6 EA per 30 days).
    Step Therapy

    Step therapy (conditional) — legend reference

    The formulary legend defines 'ST' (Step Therapy); where ST is shown next to a drug, step therapy requirements apply though specific sequences are not always enumerated in these chunks.

    • ST is an abbreviation in the formulary legend and applies when shown next to individual products.
    • Specific step sequences may be defined in separate PA/clinical criteria documents.
    Step Therapy

    Step therapy present for select agents (paliperidone ER example)

    Paliperidone ER formulations are listed with Step Therapy (ST) and quantity limits; prescribers must follow ST requirements for these formulations.

    • Paliperidone ER — ST; QL (30 EA per 30 days for some strengths; 60 EA for others).
    • Document previous therapy or reasons for exception when requesting coverage.
    Step Therapy

    Step therapy presence (general)

    Step therapy is present as a plan control (ST) and may apply to a variety of agents; providers should check the drug line for an ST flag and comply with step requirements or request an exception.

    • ST appears across multiple sections and is part of the Requirements/Limits legend.
    • If ST applies and is not followed, claims may be denied.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Documentation Required

    Prescriber supporting statement and timelines for exceptions

    Where a prescriber requests an exception to a coverage restriction (PA, QL, ST), the prescriber must provide a supporting medical statement describing why the exception is needed; standard decisions are made within 72 hours and expedited requests within 24 hours.

    • Prescriber must explain medical reasons for the exception.
    • Standard decision timeframe: 72 hours; expedited: 24 hours when appropriate.
    Documentation Required

    Medicare Part B vs D documentation note

    Formulary entries marked 'B/D' indicate Part B vs Part D coverage may apply and the prescriber may need to submit documentation describing the drug use and setting to determine the correct Medicare benefit.

    • B/D designation signals potential Part B (medical) vs Part D (drug) determination.
    • Provider documentation about use and site-of-care may be required for benefit determination.
    Documentation Required

    Home infusion documentation requirement note

    Products designated 'HI' (Home Infusion) may be covered under the medical benefit and require documentation supporting home infusion services; providers should supply documentation for HI‑designated IV/reconstituted formulations.

    • Examples of HI designations include vancomycin IV reconstituted strengths and cefazolin, cefepime, ceftazidime, ceftriaxone.
    • Contact Customer Care for medical‑benefit/home infusion coverage details.
    Documentation Required

    Quantity limits require supporting documentation

    Quantity limits (QL) are applied to many products; providers must document the prescribed quantity and indication when requesting quantities that approach or exceed the listed QL.

    • Examples: Sodium Channel Agents group — QL 1100 mL per 30 days; donepezil 10 mg — QL 60 EA per 30 days.
    • Exceeding QL may require PA or lead to denial.
    Documentation Required

    Documentation for PA-listed drugs

    When 'PA' is listed in the Requirements/Limits field for a drug, prior authorization documentation must be submitted to support coverage; PA requests should include drug name, strength, quantity, and clinical rationale.

    • PA requests should reference the formulary Requirements/Limits for the specific product.
    • Include clinical justification and prior therapy history when applicable.
    Documentation Required

    Documentation for PA (prescriber must specify details)

    Prescribers must specify drug, strength, quantity and relevant clinical details when requesting prior authorization; pharmacy claims should document PA and adhere to the drug's QL.

    • Document PA approval and QL on pharmacy claims for audit and payment.
    • Provide clinical details (diagnosis, prior therapies, dosing) in PA requests.
    Note
    Note
    Billing Rule

    Document PA and QL on claims

    Document prior authorization approvals and quantity‑limit justifications on claims; for products with QL (e.g., REPATHA 2 mL per 28 days) ensure the claim reflects the authorized quantity and PA information.

    • Pharmacy claims should include PA identifiers and match QL limits.
    • Examples: REPATHA variants show PA and specific mL QLs that must be observed on claims.
    Note
    Note

    Formulary abbreviations (reference for providers)

    Formulary abbreviations (PA, QL, ST, ED, HI, B/D, LA, NE) are defined in the legend and must be referenced when submitting authorization requests or documentation.

    • PA = Prior Authorization; QL = Quantity Limits; ST = Step Therapy; ED = Excluded Drug; HI = Home Infusion; B/D = Part B vs Part D.
    • Use the Requirements/Limits field as the basis for authorization documentation.
    Note
    Note
    Note
    Denial Risk

    Not obtaining required prior authorization may result in noncoverage

    Not obtaining a required prior authorization may result in the plan not covering the drug; providers should secure PA to avoid noncoverage or denial of claims.

    • The formulary states that without PA, Priority Health Medicare may not cover the drug.
    • Providers should verify PA status prior to dispensing.
    Denial Risk

    Prior Authorization Risk — missing PA may trigger denial

    Failure to obtain prior authorization where required may lead to claim denial or noncoverage by Priority Health Medicare for the listed drug.

    • PA is required for many specialty/Tier 5 drugs; missing PA can trigger denial.
    • Members or prescribers may request an exception, but PA remains required unless exception approved.
    Prior Authorization

    Prior Authorization triggers for specific products (XIFAXAN example)

    Specific products trigger prior authorization (e.g., XIFAXAN 200 mg and 550 mg require PA and have QLs); lack of PA for these products may lead to noncoverage.

    • XIFAXAN 200 mg — PA; QL 9 EA per 30 days.
    • XIFAXAN 550 mg — PA; QL 60 EA per 30 days.
    Denial Risk

    Prior authorization required for listed agents — denial risk

    Many listed specialty agents will be denied if PA is not obtained (examples across the formulary include NEXLETOL, NEXLIZET, REPATHA and multiple specialty neurology, oncology, and pulmonary agents).

    • REPATHA variants — PA required; QL specified.
    • Specialty T5 drugs commonly require PA and may be denied without it.
    Denial Risk

    Step therapy may trigger denial if not followed

    Failure to follow step therapy requirements (where 'ST' is indicated) may result in denial of coverage for the requested drug; providers should verify and document prior treatment attempts or request an exception.

    • Examples: FETZIMA and eletriptan list ST and QL.
    • If ST is not met, submit clinical rationale for exception.
    Denial Risk

    Prior Authorization required for oncology oral drugs — denial risk

    Many oncology oral drugs listed as Tier 5 require prior authorization and claims may be denied without PA; providers must secure PA prior to dispensing these oral oncology agents.

    • Examples: ERLEADA, XTANDI, PIQRAY, QINLOCK and many molecular targeted therapies show PA; QL applies.
    • Tier 5 oral oncology agents are frequently PA‑controlled.
    Denial Risk

    Prior Authorization required — missing PA may trigger denial

    Prior authorization (PA) is required for numerous listed drugs; absence of PA documentation on the claim may result in denial or noncoverage of the medication.

    • VERSACLOZ, LIVTENCITY, PREVYMIS are examples of drugs requiring PA where coverage may be denied without it.
    • Check each product's Requirements/Limits for PA and QL details.
    Denial Risk

    Quantity limit triggers — exceeding QL may lead to denial

    Quantity limits (QL) are enforced for many products; claims requesting quantities above the listed QL may be denied or require additional review and supporting documentation.

    • Examples: AMVUTTRA — QL 0.5 mL per 90 days; ENDARI — QL 180 EA per 30 days; VYNDAMAX — QL 30 EA per 30 days.
    • Exceeding QL generally requires PA or clinical justification.
    Prior Authorization

    Prior authorization triggers for specified branded specialty agents

    Prior authorization is required for many branded specialty agents (examples include LUPRON DEPOT kits, SIGNIFOR, SOMAVERT, TRELSTAR MIXJECT); secure PA to obtain coverage for these products.

    • LUPRON DEPOT (1‑month and 3‑month kits) — PA.
    • SIGNIFOR and SOMAVERT — PA noted in Requirements/Limits.
    Denial Risk

    Quantity limit triggers (biologic mL examples)

    Exceeding quantity limits for biologics and injectables (e.g., COSENTYX 8 mL/28 days; DUPIXENT mL per 30 days) can result in denial or restricted coverage; adhere to the QL listed on each drug line.

    • COSENTYX 300 mg — PA; QL 8 mL per 28 days.
    • DUPIXENT — PA; QL varies by presentation (e.g., 3.42 mL or up to 8 mL per 30 days).
    Denial Risk

    Exclusion denial risk for ED‑listed drugs (benz onatate example)

    Benzonatate is listed as an Excluded Drug (ED) on the formulary; claims for excluded drugs may be denied and are not normally covered by the Medicare prescription drug benefit.

    • ED = Excluded Drug; benzonatate is specifically marked ED in the respiratory agents section.
    • Excluded drugs do not count toward catastrophic coverage and are not normally covered.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Per-Product Quantity Limit Details

    XARELTO 10MG — 30 tablets per prescription
    XARELTO 10 mg (example)30 tablets per prescription (example of quantity limit described in coverage restrictions)
    Policy note on QL and PAFormulary indicates QL and PA may be applied per drug; check specific product lines for exact limits
    Supply context30 tablets per 30-day prescription may be in addition to standard 1-month or 3-month supply rules
    diclofenac sodium external solution 1.5% — QL 750 ML per 30 days
    diclofenac sodium external solution 1.5%QL 750 ML per 30 days
    Formulary locationListed under Nonsteroidal Anti-Inflammatory Drugs with QL noted
    Supply intervalQuantity limit applies per 30-day period
    fentanyl transdermal patch 72 hour — QL 10 EA per 30 days
    Fentanyl transdermal patch 72 hour (various mcg/hr)QL 10 EA per 30 days
    Formulary groupingListed among opioid analgesics with QL specified
    Applies to patch presentationsLimit expressed as each (EA) per 30 days
    methadone hcl oral solution 10 mg/5ml — QL 600 ML per 30 days
    Methadone HCl oral solution 10 mg/5 mlQL 600 ML per 30 days
    Other methadone strengths5 mg/5 ml listed with QL 1200 ML per 30 days; tablets have EA-based QLs
    Formulary noteQuantity limits vary by formulation and strength
    KLOXXADO — QL 2 EA per 30 days
    KLOXXADO (naloxone nasal spray)QL 2 EA per 30 days
    Naloxone formulationsMultiple naloxone presentations listed; KLOXXADO specifically QL 2 EA per 30 days
    Tier infoListed with tier and QL in formulary
    vancomycin hcl oral capsule 125 mg — QL 80 EA per 30 days
    Vancomycin HCl oral capsule 125 mgQL 80 EA per 30 days
    Vancomycin HCl oral capsule 250 mgQL 160 EA per 30 days
    Vancomycin entry summaryOral and IV forms listed; IV forms designated HI where applicable
    linezolid oral tablet — QL 56
    Linezolid oral tabletQL 56 EA per 28 days
    Linezolid formulationsIV and oral forms listed; tablets have 56 EA per 28 days QL
    Supply intervalLimit specified per 28-day period
    brivaracetam oral solution — QL 600
    Brivaracetam oral solutionQL 600 ML per 30 days
    Brivaracetam tabletsQL 60 EA per 30 days (tablets entry)
    PA statusBrivaracetam entries include PA where indicated
    Sodium Channel Agents (group) — QL 1100
    Sodium Channel Agents (group)QL 1100 ML per 30 days
    Group-level QLGroup QL applies across sodium channel agent formulations as listed
    DocumentationQuantity limits require supporting documentation when applied
    eslicarbazepine acetate 200/400/600/800 mg — QLs
    Eslicarbazepine acetate 200/400 mgQL 30 EA per 30 days
    Eslicarbazepine acetate 600/800 mgQL 60 EA per 30 days
    Actionable itemEslicarbazepine QLs by strength — confirm correct strength when submitting PA/claim
    lacosamide oral solution — QL 1200
    Lacosamide oral solutionQL 1200 ML per 30 days
    Lacosamide oral tabletQL 60 EA per 30 days
    Formulation-specific QLsDifferent QLs apply to solution vs tablet forms
    donepezil 10 mg — QL 60
    Donepezil 10 mgQL 60 EA per 30 days
    Donepezil 5 mgQL 30 EA per 30 days
    Dispensed formsDispersible/tablet forms have same or similar QLs as noted
    memantine hcl er — QL 30
    Memantine HCl ERQL 30 EA per 30 days
    Memantine oral solutionQL 300 ML per 30 days
    Other memantine tablet QLQL 60 EA per 30 days for 10 mg tablet
    aprepitant — QL 6
    AprepitantQL 6 EA per 30 days
    Emetogenic adjunctsSome agents also require PA or B/D designation as noted
    Use for claimsDocument dose and quantity when requesting PA or override
    EMGALITY (various) — QL 1-3
    EMGALITY (various presentations)QL 1–3 ML per 30 days depending on presentation
    AIMOVIG / NURTEC contextOther CGRP agents listed with PA and QL (e.g., AIMOVIG QL 1 ML per 30 days)
    Presentation-specific QLsCheck dosage/presentation to determine applicable QL
    abiraterone acetate 250 mg — QL 120
    Abiraterone acetate 250 mgQL 120 EA per 30 days
    Multiple oncology examplesMany oncology agents have QLs such as 30, 60, 120 EA per 30 days depending on product
    PA commonNumerous oncology entries also require PA in addition to QL
    XPOVIO therapy packs QLs — examples
    XPOVIO therapy packsExamples: QL 8 EA per 28 days; 16 EA per 28 days; 4 EA per 28 days; 32 EA per 28 days depending on pack
    XPOVIO variantsMultiple dosing packs listed with distinct 28-day QLs
    Submit PA when requiredTherapy packs often require PA as shown in formulary
    PIQRAY (250 mg/300 mg) — QL 56
    PIQRAY (250 mg / 300 mg daily dose)QL 56 EA per 28 days
    QINLOCKQL 90 EA per 30 days
    Oncology oral agentsMany require PA in addition to specified QL
    QINLOCK — QL 90
    QINLOCKQL 90 EA per 30 days
    Usage noteListed as Tier 5 with PA and QL
    Claim submissionInclude quantity and strength per QL when requesting PA
    VITRAKVI ORAL SOLUTION — QL 300
    VITRAKVI ORAL SOLUTIONQL 300 ML per 30 days
    Capsule/tablet variantsOther VITRAKVI capsule QLs (60–90 EA per 30 days) listed separately
    PA requirementPA applies to VITRAKVI entries
    INVEGA TRINZA formulations — varying ML per 90 days
    INVEGA TRINZA formulationsQL varies by formulation (examples: 0.88 ML per 90 days; 1.32 ML per 90 days; 3.5 ML per 180 days) — check specific product line
    INVEGA HAFYERAQL 3.5 ML per 180 days for 1092 mg/3.5 ML presentation
    Long-interval injectable QLsMany injectable depot products have ML-based QLs per 30/90/180 days
    ZYPREXA RELPREVV (210/300/405 mg) — QLs 2/2/1
    ZYPREXA RELPREVV 210 mgQL 2 EA per 30 days
    ZYPREXA RELPREVV 300 mgQL 2 EA per 30 days
    ZYPREXA RELPREVV 405 mgQL 1 EA per 30 days
    VERSACLOZ — QL 540
    VERSACLOZQL 540 ML per 30 days
    PA requirementVERSACLOZ listed with PA and QL
    Formulation noteLiquid/solution presentation QL expressed in ML
    PREVYMIS / EPCLUSA — QLs 120 / 28-56
    PREVYMIS oral packetQL 120 EA per 30 days
    EPCLUSA oral packet/tabletQL 28–56 EA per 28 days depending on packet strength
    PA appliesMany HCV/HBV antiviral packets require PA as indicated
    ISENTRESS / emtricitabine-tenofovir / PREZISTA examples
    ISENTRESS (various forms)QL range 60–300 EA per 30 days depending on form (e.g., HD, packets, tablets)
    Emtricitabine-tenofovir DF tabletsQL 30 EA per 30 days
    PREZISTA oral suspensionQL 400 ML per 30 days
    PAXLOVID and benzodiazepine/other varied QLs
    PAXLOVID (various strengths)QL examples 22–60 EA per 180 days depending on strength/pack
    Benzodiazepines examplesAlprazolam QL 150 EA/30 days; clonazepam up to 300 EA/30 days; diazepam 120 EA/30 days
    Methylphenidate solutionQL up to 1500 ML per 30 days for oral solution presentations
    MOUNJARO/OZEMPIC/RYBELSUS/TRULICITY examples
    MOUNJARO / OZEMPIC / RYBELSUS / TRULICITY examplesMOUNJARO QL 2 ML per 28 days; OZEMPIC QL 3 ML per 28 days; RYBELSUS QL 30 EA per 30 days; TRULICITY QL 2 ML per 28 days
    TRIJARDY XRQL 30 EA or 60 EA per 30 days depending on strength
    Formulary tier/supply noteTier 5 products limited to 30-day supply where applicable
    mifepristone 300 mg — QL 120
    mifepristone 300 mgQL 120 EA per 30 days
    PA noteMifepristone listed with PA and QL in formulary
    Use in exceptionsExceptions may be requested per standard process if clinically indicated
    TRIJARDY XR / ELIQUIS / XARELTO examples
    TRIJARDY XRQL 30 or 60 EA per 30 days depending on strength
    ELIQUIS (various packs)QL range 30–592 EA per 30 days depending on pack/strength
    XARELTO 10 mgQL 30 EA per 30 days (example) — actionable: confirm tablet count per Rx
    Enoxaparin prefilled syringes — QL examples by ML
    Enoxaparin prefilled syringes (30/40/60 mg)QL examples: 18 ML, 24 ML, 36 ML per 30 days depending on strength (30 mg = 18 ML; 40 mg = 24 ML; 60 mg = 36 ML)
    Fondaparinux examplesQL examples in ML per 30 days vary by strength (e.g., 12–24 ML per 30 days)
    HI/B/D designationSome parenteral anticoagulant products may have HI or B/D billing designations
    NEXLETOL / NEXLIZET / REPATHA examples
    NEXLETOLQL 30 EA per 30 days
    NEXLIZETQL 30 EA per 30 days
    REPATHA familyREPATHA QL 2 ML per 28 days; REPATHA PUSHTRONEX QL 3.5 ML per 30 days
    methylphenidate oral solution — QL 1500
    Methylphenidate oral solution 10 mg/5 mlQL 1500 ML per 30 days
    Methylphenidate tablet QLsVarious ER/LA tablets have QLs 30–90 EA per 30 days depending on formulation
    Claiming noteLarge-volume solution QLs require correct ML units on claim
    pregabalin — QL 90
    Pregabalin (various strengths)QL commonly 90 EA per 30 days for many strengths; 60 EA for higher strengths
    Solution formPregabalin oral solution listed with QL 900 ML per 30 days in some entries
    Tier infoCheck specific strength for exact QL when submitting PA/claim
    Topical QL examples (creams/lotions)
    Clotrimazole-betamethasone external creamQL 120 GM per 30 days
    Clotrimazole-betamethasone external lotionQL 120 ML per 30 days
    Fluorouracil external cream 5%QL 40 GM per 30 days
    permethrin / mupirocin / clindamycin external — QLs
    Permethrin external creamQL 120 GM per 30 days
    Mupirocin externalQL 44 GM per 30 days
    Clindamycin phosphate externalQL 60 GM/ML per 30 days depending on formulation
    FASENRA / LOKELMA / RELISTOR examples
    FASENRA subcutaneous prefilled syringeQL 0.5 ML per 30 days
    LOKELMA oral packet 10 GMQL 90 EA per 30 days
    RELISTOR ORALQL 90 EA per 30 days
    AMVUTTRA / ENDARI / VYNDAMAX / testosterone examples
    AMVUTTRAQL 0.5 ML per 90 days
    ENDARIQL 180 EA per 30 days
    VYNDAMAXQL 30 EA per 30 days
    Testosterone transdermal gel (various)QL varies by formulation — examples: 150 GM, 300 GM, 37.5 GM, 75 GM, 180 ML per 30 days
    MYRBETRIQ / icatibant / COSENTYX examples
    MYRBETRIQ oral suspensionQL 300 ML per 30 days
    icatibant acetate / SAJAZIRQL 18 ML per 30 days
    COSENTYX (300 mg)QL 8 ML per 28 days
    DUPIXENT / SKYRIZI presentations — QLs
    DUPIXENT (200 mg / 300 mg presentations)QL 3.42 ML (200 mg) or up to 8 ML (300 mg) per 30 days depending on presentation
    SKYRIZI presentationsQL options: 1 ML per 28 days; 1.2 ML per 56 days; 2.4 ML per 56 days depending on presentation
    Dose/presentation importanceEnsure correct presentation selected to apply proper QL
    OTEZLA and multiple long-interval/specialty QLs
    OtezlaQL 60 EA per 30 days (tablet) or 55 EA per 28 days (therapy pack)
    Long-interval vaccine examplesMRESVIA 0.5 ML per 720 days; PENBRAYA 2 EA per 720 days; VIVOTIF 4 EA per 720 days; SHINGRIX 1 ML per 999 days (prefill)
    RESTASISQL 60 EA per 30 days (single-use) or 5.5 ML per 30 days (multidose)
    olopatadine / QVAR / epinephrine examples
    Olopatadine HCl nasalQL 30.5 GM per 30 days
    QVAR REDIHALERQL 21.2 GM per 30 days
    Epinephrine auto-injectorQL 4 EA per 30 days
    Inhaler and pump QL examples
    Fluticasone-salmeterol inhalersQL 1 EA or 60 EA per 30 days depending on product
    INCRUSE / ANORO / TRELEGY / WIXELAQL 30–60 EA per 30 days
    BREYNAQL 10.3 GM per 30 days
    KALYDECO / ORKAMBI / TRIKAFTA examples
    KALYDECO / ORKAMBI / TRIKAFTAQL examples vary by product — e.g., KALYDECO QL 56 EA per 28 days; ORKAMBI QL 60 EA per 30 days; TRIKAFTA QL 56–84 EA per 28/30 days
    Pulmonary cystic fibrosis agentsMany CF agents require PA and have QLs listed per pack or packet
    PULMOZYMEB/D designation noted for some inhaled/nebulized formulations
    pirfenidone — QL 270
    PirfenidoneQL 270 EA per 30 days
    Pulmonary fibrosis agentsPirfenidone and OFEV listed with PA and QL (60 EA per 30 days for OFEV)
    Claim notePA required for many antifibrotic therapies; include indication and quantity

    Home Infusion and Benefit Determinations

    Documentation Required

    Document home infusion (HI) eligibility and supply requirements

    Products marked 'HI' (Home Infusion) indicate potential medical benefit coverage and may require documentation supporting home infusion services; contact Customer Care for specifics.

    Documentation Required

    Document HI designation for IV/reconstituted formulations

    Multiple intravenous/reconstituted formulations are designated HI; providers must document home infusion needs and may need to bill through the medical benefit when HI applies.

    Documentation Required

    Use B/D and HI flags to determine site/benefit and document accordingly

    B/D and HI annotations influence site-of-care and benefit determination; when these flags appear, providers must document the setting and follow billing guidance for Part B or medical coverage.

    Billing Rule

    Document site-of-care when HI affects delivery/billing

    Home infusion designation (HI) may change where therapy is delivered and billed (medical benefit vs pharmacy); providers should document site-of-care to support correct billing.

    Billing Rule

    B/D and HI flags affect billing and site-of-care

    B/D and HI annotations affect site-of-care and billing; products marked HI may be covered under the medical benefit and require home infusion documentation and billing to the appropriate benefit.

    Billing Rule

    Home infusion designation affects delivery and billing

    Home infusion (HI) designation indicates medical‑benefit coverage for certain IV/infusion products; providers must document home infusion needs and follow medical‑benefit billing rules when HI applies.

    Terminology and Abbreviation Key

    Generic drugs definition
    Generic drugsFDA-approved drugs with same active ingredient as brand — may be substituted per state law
    Biosimilars / original biologicalsBiological products have biosimilars; interchangeable biosimilars may be substituted per state law
    Coverage noteFormulary references biological products and biosimilars in listings; substitutions subject to state law
    Original biological products and biosimilars
    Original biological products and biosimilarsBiological products are complex drugs; biosimilars are alternatives and some are interchangeable and may be substituted depending on state law
    Substitution rulesInterchangeable biosimilars may be substituted without new prescription in some states
    Formulary implicationPlan may add biosimilars and re-tier originator products as noted elsewhere
    B/D (Part B vs Part D) definition
    B/D abbreviationB/D = Part B vs. Part D — drug may require prior authorization and documentation to determine coverage setting
    ImplicationProviders may need to submit use and setting information to determine Part B vs Part D coverage
    Where listedB/D shown in formulary abbreviation list and applied next to certain injectables/infusible products
    PA (Prior Authorization) definition
    PAPA = Prior Authorization — approval required from Priority Health Medicare before the drug is filled
    ConsequenceFailure to obtain PA may result in noncoverage
    DocumentationSubmit supporting medical information per formulary Requirements/Limits when PA is indicated
    HI (Home Infusion) definition
    HI (Home Infusion)HI = Home Infusion — this drug may be covered under the medical benefit and supplied via home infusion services; contact Customer Care for details
    ImplicationHI designation affects site-of-care billing and may require documentation
    ExamplesMultiple IV/reconstituted formulations (e.g., vancomycin IV, cefazolin) marked HI in formulary
    QL (Quantity Limit) definition
    QL (Quantity Limit)QL = Quantity Limit — maximum amount of drug covered per specified time period (examples shown per product)
    Units usedQLs expressed in EA (each), ML (milliliters), or GM (grams) depending on formulation
    EnforcementClaims exceeding QL may be denied or require additional review/PA
    HI / QL / PA (alternate definitions)
    HI (alternate reference)Home Infusion designation indicates product subject to home infusion handling/supply and special requirements
    QL (alternate reference)Quantity Limits are maximum quantities allowed per specified time (e.g., 56 EA per 28 days)
    PA (alternate reference)Prior Authorization = pre-approval required before coverage
    QL definition (alternate)
    QL clarificationQL = maximum quantity allowed per specified time period (formulary lists EA/ML/GM as appropriate)
    ExampleLinezolid oral tablet QL 56 EA per 28 days
    Provider actionProvide documentation when requesting quantities above QL
    PA definition (alternate)
    PA definition (alternate)Prior Authorization — pre-approval required before coverage is provided; indicated by 'PA' next to drug entries
    Provider stepsSubmit PA request with drug, strength, quantity and supporting clinical rationale per formulary guidance
    Denial riskClaims may be denied without PA where 'PA' is listed
    Tier 5 definition (specialty, 30-day supply)
    Tier 5 (Specialty)Tier 5 = Specialty; Tier 5 drugs are limited to a 30-day supply
    ImplicationSpecialty-tier drugs often require PA and have QLs; dispensing limited to 30 days per formulary note
    Where statedTier note present in formulary legend and repeated throughout document
    Abbreviations used in formulary (legend)
    Abbreviation key (selected)B/D (Part B vs Part D); PA (Prior Authorization); QL (Quantity Limits); ST (Step Therapy); HI (Home Infusion); LA (Limited Availability); ED (Excluded Drug)
    UnitsEA = Each; ML = Milliliter; GM = Gram
    Legend usageAbbreviations are defined in the formulary legend and used next to drug entries to indicate requirements/limits

    Step Therapy Rules and Affected Agents

    Step therapy overview
    Member may be required to try specified lower-step drugs before coverage of alternatives
    Step therapy (ST) meaning
    ST indicates member must try specified first-line drugs before alternatives will be covered
    DrugStep therapy
    DIFICID oral suspension
    ST; QL (136 ML per 10 days)
    DIFICID oral tablet
    ST; QL (20 EA per 10 days)
    Example productStep therapy / Notes
    FETZIMA
    Requirements/Limits = ST; QL (30 EA per 30 days); NE
    TRINTELLIX
    Listed among antidepressants with ST indicated where shown
    eletriptan
    Requirements/Limits = ST; QL (6 EA per 30 days)
    Legend / AbbreviationMeaning
    ST
    Step Therapy — member must try specified first-line drugs before alternatives are covered
    PA
    Prior Authorization — approval required before filling where indicated
    DrugStep therapy / Requirement
    paliperidone ER (1.5, 3, 6, 9 mg)
    Requirements/Limits = ST; QL (30 EA per 30 days for some strengths; 60 EA per 30 days for others)
    Plan controlNote
    ST referenced as plan control
    Step therapy is a plan feature but specific sequences are not enumerated in these segments
    Plan control mentionContext
    Step therapy (ST) referenced in formulary legend and entries
    Used as an available plan control though specific step sequences may not be listed in the segment
    ProductStep therapy
    calcitriol external (example context)
    Noted as requiring ST where indicated (some external calcitriol products show ST)
    ProductStep therapy
    clotrimazole-betamethasone external cream
    Requirements/Limits = ST; QL (120 GM per 30 days)
    clotrimazole-betamethasone external lotion
    Requirements/Limits = QL (120 ML per 30 days)
    LegendApplies to
    ST (Step Therapy)
    Indicates member may be required to try specified first-line drugs before alternatives will be covered; appears in legend and on drug lines such as clotrimazole-betamethasone and calcitriol external
    Ophthalmic agentStep therapy
    difluprednate (ophthalmic)
    Requirements/Limits = ST
    loteprednol etabonate ophthalmic (gel/suspension)
    Requirements/Limits = ST
    LegendNote
    ST appears in the document legend and on select product lines
    When ST is shown the member must try specified first-line drugs before coverage of alternatives; specific step sequences are provided per drug line when included

    Biosimilar Substitution and Tiering

    Note

    Formulary may add biosimilars and re‑tier originals — monitor updates

    Plan may immediately add interchangeable biosimilars and re‑tier original biologicals; providers should be aware that formulary versions can change and review updates on the plan website.

    Biological products are more complex than small-molecule drugs and, where applicable, the formulary may list original biologics and biosimilars separately. The plan may add biosimilars (including interchangeable biosimilars) and re‑tier or remove original biological products over time; interchangeability and substitution depend on FDA designation and applicable state law.

    Policy Background and Scope

    Biological products differ from traditional small-molecule generics: they are complex molecules and the market alternative is a biosimilar rather than a generic. Some biosimilars are designated as interchangeable, which may permit substitution without a new prescription depending on federal and state rules; the formulary notes the plan may adopt biosimilars and update tiering accordingly.

    MRESVIA QL 0.5 ML per 720 days; PENBRAYA QL 2 EA per 720 days; VIVOTIF QL 4 EA per 720 days; SHINGRIX QL 1 ML per 999 days (prefill) or 2 EA per 999 days (reconstituted)